Related Experiment Video
Updated: Jun 19, 2026
13:41
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
HPV vaccines: preclinical development.
1Deutsches Krebsforschungszentrum, Heidelberg, Germany. l.gissmann@dkfz.de
Archives of Medical Research
|October 27, 2009
Summary
Current human papillomavirus (HPV) vaccines use virus-like particles (VLPs) based on animal models. Further vaccine development is crucial, especially for high-burden cervical cancer regions.
Area of Science:
- Immunology
- Virology
- Vaccinology
Background:
- Knowledge of human papillomavirus (HPV) immune biology primarily derives from animal models.
- These models informed the development strategy for current HPV vaccines, which utilize virus-like particles (VLPs).
- VLPs are DNA-free viral particles constructed from 360 units of the major structural protein, L1.
Purpose of the Study:
- To review the immune biology of human papillomaviruses.
- To discuss the basis of current vaccine strategies.
- To highlight the need for second-generation HPV vaccines.
Main Methods:
- Review of existing literature on HPV immunology and vaccine development.
- Analysis of the protective mechanisms of current HPV vaccines.
- Assessment of the limitations and future directions for HPV vaccine technology.
Main Results:
- Protection against HPV infection relies on neutralizing antibodies that block virus-host cell interactions.
- Current vaccines, targeting high-risk HPV types 16 and 18, demonstrate good efficacy in preventing anogenital lesions.
- The efficacy of current vaccines underscores the importance of L1-based VLPs for inducing protective immunity.
Conclusions:
- Second-generation HPV vaccines are essential, particularly for regions with a high burden of cervical cancer.
- Further research into HPV immune responses and vaccine platforms is warranted.
- Advancing vaccine technology can address unmet medical needs in global cervical cancer prevention.
Related Concept Videos
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:51Vaccinations
Overview